Pharma Company Postpones Executive Compensation Decisions Amid FCPA Probe

In August 2010, SciClone Pharmaceuticals Inc. disclosed that the SEC and the Justice Department are investigating it for potential violations of the Foreign Corrupt Practices Act.

Unlock unlimited access to all Global Investigations Review content